J&J asks doctors to limit Natrecor use

Share this article:
In an effort to curb off-label use of its heart failure drug Natrecor, Johnson & Johnson's Scios division has unveiled a new sales force education campaign recommending that doctors only use the drug in patients whose symptoms are so severe that they have been hospitalized.
Natrecor was approved in 2001 by the FDA specifically for use in acutely ill heart-failure patients who arrived at the hospital with breathing difficulties.
However, in recent years, Natrecor has also been dispensed in outpatient clinics where patients have come in for scheduled treatments. Such outpatient use contributed to global sales of the drug reaching $400 million last year.
The new education campaign will be rolled out over the next several weeks and consists of re-training the entire Natrecor sales force and its promotional speakers regarding the recommended use of the drug. Scios said it would also create new Natrecor promotional materials for use with healthcare providers and new language in promotional speakers programs and advertising in medical journals.
The new physician guidance follows the appearance of two medical journal articles earlier this year that questioned whether the drug contributed to worsened kidney function and higher rates of death in patients. In April a panel of leading cardiologists also asked that J&J review the drug.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.